{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T21:08:14Z","timestamp":1774386494106,"version":"3.50.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.hoc.2011.09.003","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T07:50:22Z","timestamp":1320306622000},"page":"1025-1048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era"],"prefix":"10.1016","volume":"25","author":[{"given":"Nitin","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.hoc.2011.09.003_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2011.09.003_bib2","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM197707212970307","article-title":"Cure of hematologic neoplasia with transplantation of marrow from identical twins","volume":"297","author":"Fefer","year":"1977","journal-title":"N\u00a0Engl J Med"},{"issue":"8299","key":"10.1016\/j.hoc.2011.09.003_bib4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(82)92735-0","article-title":"Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation","volume":"2","author":"Clift","year":"1982","journal-title":"Lancet"},{"issue":"8299","key":"10.1016\/j.hoc.2011.09.003_bib5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(82)92736-2","article-title":"Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia","volume":"2","author":"Goldman","year":"1982","journal-title":"Lancet"},{"issue":"8378","key":"10.1016\/j.hoc.2011.09.003_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","article-title":"Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia","volume":"1","author":"Speck","year":"1984","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2011.09.003_bib7","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-03-0675","article-title":"Current trends in hematopoietic stem cell transplantation in Europe","volume":"100","author":"Gratwohl","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-104-2-155","article-title":"Marrow transplantation for the treatment of chronic myelogenous leukemia","volume":"104","author":"Thomas","year":"1986","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.hoc.2011.09.003_bib9","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2011.09.003_bib10","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V82.7.2235.2235","article-title":"Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase","volume":"82","author":"Goldman","year":"1993","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2011.09.003_bib11","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A\u00a010-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"Robin","year":"2005","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.hoc.2011.09.003_bib12","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia","volume":"338","author":"Hansen","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib13","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2011.09.003_bib14","unstructured":"Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. Accessed September 27, 2011."},{"issue":"6","key":"10.1016\/j.hoc.2011.09.003_bib15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.hoc.2011.09.003_bib16","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","article-title":"T-cell depletion of HLA-identical transplants in leukemia","volume":"78","author":"Marmont","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2011.09.003_bib17","first-page":"96","article-title":"Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow","volume":"6","author":"Buckner","year":"1978","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1978.tb03656.x","article-title":"Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation","volume":"40","author":"Goldman","year":"1978","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2141.1991.tb08581.x","article-title":"Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases","volume":"77","author":"Reiffers","year":"1991","journal-title":"Br J Haematol"},{"issue":"8911","key":"10.1016\/j.hoc.2011.09.003_bib20","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/S0140-6736(94)92589-5","article-title":"Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups","volume":"343","author":"McGlave","year":"1994","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib21","first-page":"775","article-title":"Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience","volume":"17","author":"Khouri","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2011.09.003_bib22","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood.V83.10.3068.3068","article-title":"Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML","volume":"83","author":"Deisseroth","year":"1994","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib23","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib24","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2011.09.003_bib26","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2011.09.003_bib28","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","article-title":"Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation","volume":"304","author":"Weiden","year":"1981","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2011.09.003_bib30","first-page":"1553","article-title":"Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes","volume":"23","author":"Slavin","year":"1995","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib31","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1365-2141.1999.01706.x","article-title":"Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in\u00a0vivo and in\u00a0vitro evidence for a graft-versus-leukaemia effect","volume":"107","author":"Childs","year":"1999","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib33","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1704107","article-title":"Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia","volume":"32","author":"Das","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.bmt.1704664","article-title":"Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease","volume":"34","author":"Weisser","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2011.09.003_bib37","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/sj.leu.2403730","article-title":"Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML","volume":"19","author":"Kerbauy","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2011.09.003_bib38","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2007-04-085969","article-title":"Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia","volume":"110","author":"Kebriaei","year":"2007","journal-title":"Blood"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2011.09.003_bib39","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.3816\/CLM.2009.s.021","article-title":"Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era","volume":"9","author":"Champlin","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2011.09.003_bib41","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/leu.2008.401","article-title":"Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase","volume":"23","author":"Luo","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2011.09.003_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/10428190802626624","article-title":"Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia","volume":"50","author":"Poire","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2141.2000.02123.x","article-title":"Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age","volume":"109","author":"Raiola","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2011.09.003_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-2141.2001.03074.x","article-title":"Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis","volume":"115","author":"Bornhauser","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib45","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib47","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00277-009-0737-3","article-title":"The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia\u2014a report from the German Registry covering the period from 1998 to 2004","volume":"88","author":"Bacher","year":"2009","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","article-title":"Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia","volume":"137","author":"Giralt","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib49","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.bmt.1705190","volume":"36","author":"Ruiz-Arg\u00fcelles","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.leu.2404509","article-title":"Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe\u2014impact of cost considerations","volume":"21","author":"Gratwohl","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib51","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2011.09.003_bib52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/bmt.2008.218","article-title":"Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase","volume":"42","author":"Bittencourt","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2011.09.003_bib53","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib54","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","article-title":"Stem cell transplantation for chronic myeloid leukemia in children","volume":"102","author":"Cwynarski","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2011.09.003_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin Padiatr"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.beha.2009.09.008","article-title":"CML in pregnancy and childhood","volume":"22","author":"Apperley","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib57","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.13529","article-title":"The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up","volume":"94","author":"Palandri","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","article-title":"Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials","volume":"94","author":"Silver","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib60","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib61","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.hoc.2011.09.003_bib62","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib63","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.leu.2402808","article-title":"Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias","volume":"17","author":"Shimoni","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705087","article-title":"Imatinib therapy prior to myeloablative allogeneic stem cell transplantation","volume":"36","author":"Zaucha","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib65","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"issue":"9584","key":"10.1016\/j.hoc.2011.09.003_bib66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib67","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.hoc.2011.09.003_bib68","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome\u2014positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.hoc.2011.09.003_bib69","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.hoc.2011.09.003_bib70","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib71","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2011.09.003_bib72","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/leu.2008.160","volume":"23","author":"Shimoni","year":"2009","journal-title":"Leukemia"},{"issue":"35","key":"10.1016\/j.hoc.2011.09.003_bib73","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2011.09.003_bib74","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.25092","article-title":"Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I","volume":"116","author":"Velev","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib75","first-page":"68","article-title":"Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia","volume":"15","author":"Basak","year":"2010","journal-title":"Ann Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2011.09.003_bib76","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.leukres.2008.10.020","article-title":"Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia","volume":"33","author":"Sanchez-Guijo","year":"2009","journal-title":"Leuk Res"},{"issue":"13","key":"10.1016\/j.hoc.2011.09.003_bib77","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.003_bib78","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-07-367326","article-title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias","author":"Nicolini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2011.09.003_bib79","doi-asserted-by":"crossref","unstructured":"Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood;114(26):5271\u20138.","DOI":"10.1182\/blood-2009-04-219410"},{"key":"10.1016\/j.hoc.2011.09.003_bib80","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V116.21.210.210","article-title":"A phase 1 trial of oral Ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings","volume":"116","author":"Cortes","year":"2010","journal-title":"Blood"},{"issue":"9134","key":"10.1016\/j.hoc.2011.09.003_bib81","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib82","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.hoc.2011.09.003_bib83","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2010-01-263624","article-title":"Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase","volume":"115","author":"Pavlu","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib84","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbmt.2008.08.004","article-title":"Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation","volume":"14","author":"Artz","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib85","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V94.2.384","article-title":"The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow","volume":"94","author":"Elmaagacli","year":"1999","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2011.09.003_bib86","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib87","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.bbmt.2007.08.006","article-title":"Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival","volume":"13","author":"Eapen","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib88","first-page":"3702","article-title":"Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT)","volume":"95","author":"Champlin","year":"2000","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2011.09.003_bib89","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1182\/blood-2006-05-024042","article-title":"Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation","volume":"108","author":"Schmitz","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib90","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbmt.2004.09.010","article-title":"Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia","volume":"11","author":"Oehler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2011.09.003_bib91","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation","volume":"99","author":"Weisdorf","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2011.09.003_bib92","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1200\/JCO.2008.18.7740","article-title":"HLA-identical sibling compared with 8\/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia","volume":"27","author":"Arora","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib93","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2010.05.014","article-title":"Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia","volume":"16","author":"Sanz","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib94","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/bmt.2008.164","article-title":"Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis","volume":"42","author":"Nagamura-Inoue","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1016\/j.hoc.2011.09.003_bib95","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V98.13.3569","article-title":"Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies","volume":"98","author":"Socie","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2011.09.003_bib96","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2011.09.003_bib97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2011.09.003_bib98","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2011.09.003_bib99","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2141.2003.04228.x","article-title":"T-cell depletion with Campath-1H \u201cin the bag\u201d for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival","volume":"121","author":"Chakrabarti","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib100","first-page":"1559","article-title":"Outcomes after myeloablative unrelated donor stem cell transplantation using both in\u00a0vitro and in\u00a0vivo T-cell depletion with alemtuzumab","volume":"91","author":"von dem Borne","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib101","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2008.07179.x","article-title":"Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib102","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood.V77.4.874.874","article-title":"Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse","volume":"77","author":"Hughes","year":"1991","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2011.09.003_bib103","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473","article-title":"Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation","volume":"87","author":"Lin","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2011.09.003_bib104","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.V85.9.2632.bloodjournal8592632","article-title":"Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients","volume":"85","author":"Radich","year":"1995","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2011.09.003_bib105","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2011.09.003_bib106","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V97.6.1560","article-title":"Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"97","author":"Olavarria","year":"2001","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2011.09.003_bib107","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib108","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2011.09.003_bib109","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib110","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bmt.2009.177","article-title":"Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT","volume":"45","author":"Chalandon","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2011.09.003_bib111","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood.V96.1.86","article-title":"Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission","volume":"96","author":"Craddock","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2011.09.003_bib112","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2011.09.003_bib113","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib114","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation","volume":"36","author":"Savani","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib115","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2011.09.003_bib116","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"issue":"30","key":"10.1016\/j.hoc.2011.09.003_bib117","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"Hess","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib118","first-page":"663","article-title":"A\u00a0comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation","volume":"91","author":"Weisser","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib119","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2141.2003.04599.x","article-title":"Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission","volume":"123","author":"Drummond","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2011.09.003_bib120","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.leu.2402917","article-title":"Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR","volume":"17","author":"Hui","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2011.09.003_bib121","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.2003.04756.x","article-title":"Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in\u00a0vivo purging","volume":"124","author":"Kreuzer","year":"2004","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2011.09.003_bib122","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1537-2995.2005.00175.x","article-title":"Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate","volume":"45","author":"Perseghin","year":"2005","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib123","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/10428190701799043","article-title":"Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products","volume":"49","author":"Gordon","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2011.09.003_bib124","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3109\/10428194.2010.501534","article-title":"Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy","volume":"51","author":"Bashir","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2011.09.003_bib125","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2011.09.003_bib126","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.hoc.2011.09.003_bib127","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learnt?","volume":"117","author":"Pavlu","year":"2011","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858811001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858811001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:55:52Z","timestamp":1760183752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858811001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":127,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0889858811001006"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2011.09.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2011.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}